:: Home   :: Contact ICare   :: Site Map          
 | Home | About ICare | Research | CTR Library | Register | Contact ICare
Myeloma Cancer News
Myeloma Cancer Breakthrough News
  Dec 11, 2007
ASH: Low-Dose Steroid Combo Bests High-Dose Regimen in Multiple Myeloma
  By Charles Bankhead, Staff Writer, MedPage Today

ATLANTA, Dec. 11 -- Two-year survival in newly diagnosed multiple myeloma patients improved significantly when lenalidomide (Revlimid) was given with low-dose dexamethasone rather than standard high-dose steroid therapy, according to updated results of a multicenter clinical trial.   <READ MORE>

  Nov 21, 2007
Lenalidomide Benefits in Recurrent Myeloma Detailed
  By Charles Bankhead, Staff Writer, MedPage Today

HOUSTON, Nov. 21 -- Patients with relapsed or refractory multiple myeloma had significantly improved progression-free and overall survival when treated with lenalidomide (Revlimid) and dexamethasone, compared with dexamethasone and placebo.   <READ MORE>


Oct 20, 2007
Webcast of Presentation at "Lymphoma & Myeloma 2007" held in New York, NY.


By Ruben Niesvizky, MD

Emerging therapeutic strategies for multiple myeloma: Proteasome inhibitors and immunomodulators



:: 12 Element Approach ::
Explore and supplement your therapy with ICare's unique 12-Element approach to Patient Survival.

:: Breakthrough News ::
Breaking news on research for gentler, more effective therapies and information on lifesaving treatment options.

:: ICare Bulletin Board ::
View pertinent information regarding meetings and events pertaining to cancer patients. This is also a resource for contacting other patients about information and treatment options.

Copyright ⓒ ICare.  All rights reserved.